Tetsuya Urasaki

612 total citations
53 papers, 416 citations indexed

About

Tetsuya Urasaki is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tetsuya Urasaki has authored 53 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 21 papers in Surgery and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tetsuya Urasaki's work include Cancer Immunotherapy and Biomarkers (12 papers), Head and Neck Cancer Studies (9 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Tetsuya Urasaki is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Head and Neck Cancer Studies (9 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Tetsuya Urasaki collaborates with scholars based in Japan, United States and Norway. Tetsuya Urasaki's co-authors include Yoichi Naito, Shunji Takahashi, Kenji Nakano, Naoki Fukuda, Makiko Ono, Junichi Tomomatsu, Xiaofei Wang, Akihiro Ohmoto, Yasuyoshi Sato and Hiroki Mitani and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Tetsuya Urasaki

48 papers receiving 411 citations

Peers

Countries citing papers authored by Tetsuya Urasaki

Since Specialization

Citations

This map shows the geographic impact of Tetsuya Urasaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tetsuya Urasaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tetsuya Urasaki more than expected).

Fields of papers citing papers by Tetsuya Urasaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tetsuya Urasaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tetsuya Urasaki. The network helps show where Tetsuya Urasaki may publish in the future.

Co-authorship network of co-authors of Tetsuya Urasaki

This figure shows the co-authorship network connecting the top 25 collaborators of Tetsuya Urasaki. A scholar is included among the top collaborators of Tetsuya Urasaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tetsuya Urasaki. Tetsuya Urasaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib 2024 ·Endocrine Journal ·Naoki Fukuda, Kazuhisa Toda, (unknown), Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi	1
2	301P Effectiveness and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: A preliminary report of real-world data from a single institution in Japan 2024 ·Annals of Oncology ·Yoshinari Yasuda, Tetsuya Urasaki, Ryosuke Oki, (unknown), (unknown), (unknown), Tamio Oguchi, Noboru Numao, Junji Yonese, Takeshi Yuasa	0
3	Severe drug eruption after antibiotic administration in patients receiving immune checkpoint inhibitors: A monocentric case series 2023 ·SHILAP Revista de lepidopterología ·Aya Nishizawa, Koichi Takeda, Tetsuya Urasaki, Makiko Ono, Toshiaki Mochizuki, Taro Shiga, (unknown), Takeshi Yuasa, Atsushi Murakami, Ryo Koike, (unknown), Hiroyuki Kanao, Keitaro Shimozaki, Daisuke Takahari, Takahiro Kogawa, Shunji Takahashi, Shigehisa Kitano	0
4	A case of sequential medical therapy for advanced ureteral cancer in Li–Fraumeni syndrome 2023 ·IJU Case Reports ·(unknown), (unknown), Arisa Ueki, Ryosuke Oki, Tetsuya Urasaki, Kentaro Inamura, Shunji Takahashi, Junji Yonese, Takeshi Yuasa	0
5	Comparison of Paclitaxel plus Carboplatin versus Observation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck 2023 ·Oncology ·Naoki Fukuda, Ryosuke Oki, (unknown), Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi	1
6	Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study 2023 ·PLoS ONE ·Akihiro Ohmoto, Kenji Nakano, Naoki Fukuda, Xiaofei Wang, Tetsuya Urasaki, Naomi Hayashi, (unknown), (unknown), Ryosuke Oki, Yasuyoshi Sato, Mayu Yunokawa, Makiko Ono, Masanori Saito, (unknown), Keiko Hayakawa, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Junichi Tomomatsu, Shunji Takahashi	1
7	First‐in‐human study of E7130 (a tumor microenvironment‐ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose‐escalation part 2023 ·Cancer ·Toshihiko Doi, Nobuaki Matsubara, Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, Makiko Ono, Tetsuya Urasaki, Akihiro Ohmoto, (unknown), Takashi Hisai, Hiroki Ikezawa, (unknown), Ken Ito, Taro Semba, Osamu Asano, Shunji Takahashi	3
8	The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin 2023 ·Journal of Geriatric Oncology ·Yu Fujiwara, Yasuyoshi Sato, Naomi Hayashi, Naoki Fukuda, Xiaofei Wang, Kenji Nakano, Akihiro Ohmoto, Tetsuya Urasaki, Makiko Ono, Junichi Tomomatsu, (unknown), Hiroki Mitani, Shunji Takahashi	5
9	A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients 2022 ·Endocrine ·Naoki Fukuda, Kazuhisa Toda, (unknown), Akihiro Ohmoto, Ryosuke Oki, (unknown), Xiaofei Wang, Naomi Hayashi, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi	6
10	Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma 2021 ·Cancers ·Yasuyoshi Sato, Kenji Nakano, Xiaofei Wang, Naoki Fukuda, Tetsuya Urasaki, Akihiro Ohmoto, Naomi Hayashi, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Masanori Saito, (unknown), Keiko Hayakawa, Yuki Funauchi, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Shunji Takahashi	10
11	Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer 2021 ·In Vivo ·Yasuyoshi Sato, Naoki Fukuda, Yu Fujiwara, Xiaofei Wang, Tetsuya Urasaki, Akihiro Ohmoto, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi	14
12	545P First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part 2021 ·Annals of Oncology ·Toshihiko Doi, (unknown), Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, (unknown), Tetsuya Urasaki, Akihiro Ohmoto, Takashi Hisai, (unknown), Hiroki Ikezawa, Satoshi Shiba, Kei Ito, Osamu Asano, Shuhei Takahashi	1
13	Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib 2021 ·Anticancer Research ·Naoki Fukuda, Kazuhisa Toda, Akihiro Ohmoto, Xiaofei Wang, Naomi Hayashi, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi	7
14	Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial 2020 ·SHILAP Revista de lepidopterología ·Yukiko Sato, Naoki Fukuda, (unknown), Tetsuya Urasaki, Akihiro Ohmoto, Kenji Nakano, Mayu Yunokawa, (unknown), (unknown), Junichi Tomomatsu, Shunji Takahashi	1
15	Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients 2020 ·Cancer Reports ·Naoki Fukuda, Mayu Yunokawa, Yu Fujiwara, Xiaofei Wang, Akihiro Ohmoto, Naomi Hayashi, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi	7
16	Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line 2020 ·Molecular and Clinical Oncology ·Kenji Nakano, Keiko Hayakawa, Yuki Funauchi, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Junichi Tomomatsu, Makiko Ono, Shinichiro Taira, Masatoshi Nishizawa, Xiaofei Wang, Akihiro Ohmoto, Yasuyoshi Sato, Naoki Fukuda, Tetsuya Urasaki, Shunji Takahashi	6
17	Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis 2020 ·Oxford Medical Case Reports ·Kenji Nakano, Masatoshi Nishizawa, Naoki Fukuda, Tetsuya Urasaki, Xiaofei Wang, Hiroki Mitani, Shunji Takahashi	16
18	<p>Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial</p> 2020 ·Cancer Management and Research ·Yasuyoshi Sato, Naoki Fukuda, Xiaofei Wang, Tetsuya Urasaki, Akihiro Ohmoto, Kenji Nakano, Mayu Yunokawa, Makiko Ono, Yukiko Sato, Hiroki Mitani, Junichi Tomomatsu, Shunji Takahashi	12
19	A Case of gastrointestinal stromal tumor complicated by hypercalcemia induced by parathyroid hormone-related protein 2016 ·Annals of Oncology ·Tetsuya Urasaki, Yoichi Naito, Toshihiko Doi, Toshiro Nishida	3
20	Induction of the activation-related antigen CD69 on human eosinophils by type IIA phospholipase A 2 2000 ·Inflammation Research ·Tetsuya Urasaki, Jun Takasaki, Toshiro Nagasawa, Haruhiko Ninomiya	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact